<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Spits, H.</title>
    <link>http://repub.eur.nl/res/aut/9178/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Stem cell factor consistently improves thymopoiesis after experimental transplantation of murine or human hematopoietic stem cells in immunodeficient mice (Article)</title>
      <link>http://repub.eur.nl/res/pub/33288/</link>
      <pubDate>2011-09-15T00:00:00Z</pubDate>
      <description>Deficient thymopoiesis is a pivotal determinant of impaired immune competence following hematopoietic stem cell transplantation (HSCT). Stem cell factor (SCF) is essentially involved in early thymopoiesis. We evaluated whether SCF administration would improve recovery of thymopoiesis following HSCT in immunodeficient mice receiving: 1) bone marrow (BM) transplantation of congenic mice; or 2) human fetal liver HSCT in the human immune system mouse model. Following murine BM transplantation, SCF significantly enhanced thymopoiesis and peripheral T cell recovery in lymph nodes and spleen. SCF did not affect BM lymphoid progenitor recovery and/or expansion. Median thymic cellularity increased from 0.9 in PBS- to 266 × 104/thymus in SCF-treated mice (p = 0.05). Following human HSCT in human immune system mice, higher thymic cellularity was observed in SCF-treated mice. Double-negative and early double-positive thymocyte subsets increased, but especially late double-positive, CD4 single-positive, and CD8 single-positive thymocyte subsets were significantly enhanced (p &lt; 0.05). These results show that exogenous supply of SCF may significantly improve murine and human posttransplant thymopoiesis, for which the effect is probably exerted by directly promoting T cell development intrathymically rather than by enhanced entry of prethymically expanded lymphoid progenitors. Copyright </description>
    </item> <item>
      <title>Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/19956/</link>
      <pubDate>2010-02-15T00:00:00Z</pubDate>
      <description>Lymphoid tissue inducer (LTi) cells are required for lymph node formation during fetal development, and recent evidence implies a role in mucosal immunity in the adult. LTi cells share some phenotypic features of conventional natural killer (NK; cNK) cells; however, little is known to date about the relationship between these two cell types. We show that lineage- (Lin-) CD127+RORC+  LTi-like cells in human tonsil are precursors to CD56+CD127+RORC+NKp46+  cells, which together comprise a stable RORC+ lineage. We find that LTi-like cells and their CD56+ progeny can be expanded and cloned ex vivo without loss of function and without conversion into cNK cells. Clonal analysis reveals heterogeneity of cytokine production within the CD127+ LTi-like population. Furthermore, we identify within the tonsil a cNK precursor population that is characterized as Lin-CD117+CD161 +CD127-  cells. Overall, we propose that CD127 +RORC+ cells, although they share some characteristics with cNK cells, represent a functionally and developmentally distinct lineage.</description>
    </item> <item>
      <title>IL-7 enhances thymic human T cell development in "human immune system" Rag2-/-IL-2Rγc-/- mice without affecting peripheral T cell homeostasis (Article)</title>
      <link>http://repub.eur.nl/res/pub/25454/</link>
      <pubDate>2009-12-15T00:00:00Z</pubDate>
      <description>IL-7 is a central cytokine in the development of hematopoietic cells, although interspecies discrepancies have been reported. By coculturing human postnatal thymus hematopoietic progenitors and OP9-huDL1 stromal cells, we found that murine IL-7 is ∼100-fold less potent than human IL-7 for supporting human T cell development in vitro. We investigated the role of human IL-7 in newborn BALB/c Rag2-/-γc-/-mice transplanted with human hematopoietic stem cells (HSC) as an in vivo model of human hematopoiesis using three approaches to improve IL-7 signaling: administration of human IL-7, ectopic expression of human IL-7 by the transplanted human HSC, or enforced expression of a murine/human chimeric IL-7 receptor binding murine IL-7. We show that premature IL-7 signaling at the HSC stage, before entrance in the thymus, impeded T cell development, whereas increased intrathymic IL-7 signaling significantly enhanced the maintenance of immature thymocytes. Increased thymopoiesis was also observed when we transplanted BCL-2- or BCL-xL-transduced human HSC. Homeostasis of peripheral mature T cells in this humanized mouse model was not improved by any of these strategies. Overall, our results provide evidence for an important role of IL-7 in human T cell development in vivo and highlight the notion that IL-7 availability is but one of many signals that condition peripheral T cell homeostasis. Copyright </description>
    </item> <item>
      <title>Interleukin-22-producing innate immune cells: New players in mucosal immunity and tissue repair? (Article)</title>
      <link>http://repub.eur.nl/res/pub/16242/</link>
      <pubDate>2009-04-01T00:00:00Z</pubDate>
      <description>Mucosal tissues, lying at the interface with the external environment, are constantly challenged by microbial, physical and chemical assaults. To provide the necessary immune defence to such challenges, lymph nodes and Peyer's patches are formed in utero in response to inductive signals from lymphoid-tissue inducer (LTi) cells. As discussed in this Progress article, a series of recent reports has identified a population of interleukin-22-producing mucosal cells in the gut and tonsils that share features with both LTi cells (by expressing RORγt) and natural killer cells (by expressing NKp46) and that might be involved in immunity and homeostasis in mucosal tissues.</description>
    </item> <item>
      <title>T cell-independent development and induction of somatic hypermutation in human IgM+IgD+CD27+ B cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/15212/</link>
      <pubDate>2008-09-01T00:00:00Z</pubDate>
      <description>IgM+IgD+CD27+ B cells from peripheral blood have been described as circulating marginal zone B cells. It is still unknown when and where these cells develop. These IgM+IgD +CD27+ B cells exhibit somatic hypermutations (SHMs) in their B cell receptors, but the exact nature of the signals leading to induction of these SHMs remains elusive. Here, we show that IgM+IgD +CD27+ B cells carrying SHMs are observed during human fetal development. To examine the role of T cells in human IgM +IgD+CD27+ cell development we used an in vivo model in which Rag2-/-γc-/- mice were repopulated with human hematopoietic stem cells. Using Rag2 -/-γc-/- mice on a Nude background, we demonstrated that development and induction of SHMs of human IgM +IgD+CD27+ B cells can occur in a T cell - independent manner.</description>
    </item> <item>
      <title>Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/14211/</link>
      <pubDate>2008-01-01T00:00:00Z</pubDate>
      <description>The human body contains over 500 individual lymph nodes, yet the biology of their formation is poorly understood. Here we identify human lymphoid tissue-inducer cells (LTi cells) as lineage-negative RORC+ CD127+ cells with the functional ability to interact with mesenchymal cells through lymphotoxin and tumor necrosis factor. Human LTi cells were committed natural killer (NK) cell precursors that produced interleukin 17 (IL-17) and IL-22. In vitro, LTi cells gave rise to RORC+ CD127+ NK cells that retained the ability to produce IL-17 and IL-22. Postnatally, similar populations of LTi cell-like cells and RORC+ CD127+ NK cells were present in tonsils, and both secreted IL-17 and IL-22 but no interferon-γ. Our data indicate that lymph node organogenesis is controlled by an NK cell precursor population with adaptive immune features and demonstrate a previously unappreciated link between the innate and adaptive immune systems.</description>
    </item> <item>
      <title>IL-7 mediated protection against minor antigen-mismatched allograft rejection is associated with enhanced recovery of regulatory T cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/36058/</link>
      <pubDate>2007-08-01T00:00:00Z</pubDate>
      <description>Background and Objectives: Interleukin-7 (IL-7) has been studied for its possible immunorestorative capacities following stem cell transplantation and has been shown to enhance post-transplant immune recovery predominantly by peripheral T-cell expansion. A major concern of IL-7 is its possible aggravating effect on graft-versus-host and host-versus-graft reactivity. Design and Methods: To study the effect of IL-7 on host-versus-graft reactivity, we applied IL-7 in an experimental transplantation model using RAG-1-/-mice supplied with B6 CD45.1 congenic T cells as recipients of T-cell depleted allogeneic bone marrow grafts. Results: Rejection of minor antigen-mismatched bone marrow was significantly reduced in IL-7 treated recipients compared with PBS treated control mice. Rejection was observed in 2 out of 18 IL-7 treated mice compared with 9 out of 17 PBS treated mice (11% vs. 53%; p=0.012). IL-7 administration resulted in enhanced recovery of peripheral blood CD4+CD25+regulatory T cells (Treg) with a concomitant increase in peripheral blood Foxp3 mRNA expression. IL-7Rα (CD127) was expressed by the vast majority of CD4+Foxp3+T cells. The incidence of graft rejection following fully MHC mismatched bone marrow transplantation was not reduced nor enhanced by IL-7 administration. Interpretation and Conclusions: Post-transplant IL-7 administration protects against minor antigen-mismatched bone marrow rejection, which may be due to enhanced Treg recovery. </description>
    </item> <item>
      <title>Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants (Article)</title>
      <link>http://repub.eur.nl/res/pub/8154/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Interleukin-7 (IL-7) has been shown to enhance thymic output of newly
      developed T cells following bone marrow transplantation (BMT) in mice. In
      addition, IL-7 may affect peripheral expansion of T cells. In order to
      study the relative contribution of thymopoiesis versus peripheral T-cell
      expansion in the setting of compromised thymopoiesis, we have applied IL-7
      in an experimental stem cell transplantation model using T cell-deficient
      RAG-1(-/-) mice. C57BL/6 RAG-1(-/-) mice received transplants of syngeneic
      T-cell-depleted (TCD) bone marrow (Ly5.1) with or without supplemented T
      cells (Ly5.2). IL-7 was administered until day 63 after BMT. Peripheral
      blood T- and B-cell recovery was quantified by flow cytometry and
      thymopoiesis was studied by quantification of T-cell receptor
      rearrangement excision circles (TRECs). In mice receiving a T-cell-replete
      BMT, IL-7 selectively expanded mature CD45.2+ T cells without affecting
      the recovery of new bone marrow-derived CD45.1+ T cells. In contrast, IL-7
      significantly enhanced the recovery of bone marrow-derived T cells after
      TCD BMT. Quantification of TRECs in mice receiving a TCD BMT revealed that
      enhanced T-cell recovery following IL-7 treatment resulted from a strong
      expansion of newly developed naive T cells. These results suggest that
      peripheral expansion of recent thymic emigrants or mature T cells may be a
      preferential mechanism by which IL-7 enhances T-cell recovery after BMT</description>
    </item> <item>
      <title>PJA-BP expression and TCR delta deletion during human T cell differentiation (Article)</title>
      <link>http://repub.eur.nl/res/pub/8990/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>Recombination of deltaRec to psiJalpha will delete the TCR delta gene,
          which is thought to play an important role in the bifurcation of the TCR
          alphabeta versus TCR gammadelta differentiation lineages. We recently
          detected a DNA-binding protein in human thymocytes, the so-called PJA-BP,
          which recognizes the psiJalpha gene segment and might be one of the
          factors involved in the regulation of preferential deltaRec-psiJalpha
          rearrangements. We now investigate PJA-BP expression and its correlation
          with TCR delta gene deletion in thymocytes. Our electrophoretic mobility
          shift assay experiments showed that the PJA-BP is evolutionary conserved
          in human, murine and simian thymocytes. Using a large series of human
          hematopoietic malignancies (n = 30), we conclude that PJA-BP expression is
          thymocyte specific and seems to be restricted to thymocytes committed to
          the TCR alphabeta lineage. Analysis of seven well-defined human thymocyte
          subpopulations showed that preferential deltaRec-psiJalpha rearrangements
          as well as PJA-BP expression can be detected from the immature
          CD34-/CD1+/CD3-/CD4+/CD8alpha+beta- thymocyte differentiation stage
          onwards. These experiments indicate that expression of PJA-BP in human
          thymocytes starts simultaneously with preferential deltaRec-psiJalpha
          rearrangements, which supports our hypothesis that PJA-BP is one of the
          factors involved in the preferential recombination of deltaRec to
          psiJalpha.</description>
    </item>
  </channel>
</rss>